Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 899507-36-9 Chemical Structure| 899507-36-9

Structure of A 438079
CAS No.: 899507-36-9

Chemical Structure| 899507-36-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

A 438079 is a competitive P2X7 receptor antagonist (pIC50 = 6.9 for the inhibition of Ca2+ influx in the human recombinant P2X7 cell line).

Synonyms: A 438079

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of A 438079

CAS No. :899507-36-9
Formula : C13H9Cl2N5
M.W : 306.15
SMILES Code : ClC1=C(Cl)C(C2=NN=NN2CC3=CC=CN=C3)=CC=C1
Synonyms :
A 438079
MDL No. :MFCD09971142

Safety of A 438079

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H228-H315-H319
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
ESdM cells 10 μM 1 h Reversed METH-induced microglial migration and phagocytosis PMC4847215

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Single Prolonged Stress (SPS) model Intracerebroventricular injection 3 μg/kg Once daily for 7 days Blocking P2X7Rs prevented the SPS-induced impaired fear extinction and extinction of cue-induced center avoidance in male and female rats, suggesting that SPS activates P2X7Rs which increase inflammation to produce a PTSD-like phenotype. PMC10106407
Rats Single prolonged stress (SPS) model Intracerebroventricular injection 3 μg/kg Once daily for 7 days Blocking P2X7Rs prevented the SPS-induced impaired fear extinction and extinction of cue-induced center avoidance in male and female rats PMC10106407
Rats Transient global cerebral ischemia/reperfusion injury model Intracerebroventricular injection 3 μg Single administration, lasting for 7 days To investigate the protective effects of A-438079 on transient global cerebral ischemia/reperfusion injury, the results showed that A-438079 significantly increased survival rates, reduced neuronal death and DNA cleavage, and improved behavioral deficits. PMC3418181
Mice PPT1 KI mouse model Intraperitoneal injection 30 mg/kg Twice a day for two days A 438079 significantly reduced the number and duration of seizures in PPT1 KI mice and reduced the number of microglia in hippocampal CA1 and CA3 regions. PMC9144763
BALB/cJ and C3H/HeN mice Bone cancer pain model Subcutaneous injection 300 μM/kg Single administration, assessed at 30 and 60 minutes post administration To investigate the effect of A-438079 on bone cancer pain-related behaviours, results showed that A-438079 failed to alleviate bone cancer pain-related behaviours. PMC6463294
Mice PPT1 KI mouse model Intraperitoneal injection 30 mg/kg Twice a day for two days A 438079 significantly reduced the duration and number of seizures in PPT1 KI mice and decreased the number of microglia in hippocampal CA1 and CA3 regions. PMC9144763

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.27mL

0.65mL

0.33mL

16.33mL

3.27mL

1.63mL

32.66mL

6.53mL

3.27mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories